Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- February 20, 2026 WASHINGTON, Feb. 20, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Bysanti (milsaperidone) tablets, a first line therapy for the acute…
- 20 February 2026 — AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lymphocytic leukemia (CLL)…
- Basel, February 18, 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announced that the US Food and Drug Administration (FDA) has approved an expanded label for Enzeevu (aflibercept-abzv), to include…
- HORSHAM, P.A. (February 17, 2026) – Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for Rybrevant Faspro (amivantamab and…
- RALEIGH, N.C., Feb. 17, 2026 /PRNewswire/ — Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that the U.S. Food and Drug…
- PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Feb. 17, 2026– Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for Wakix® (pitolisant) tablets…
- MONDAY, Feb. 23, 2026 — A new clinical classification system is presented to define the severity of an acute pulmonary embolism (PE) and assist in developing adult treatment strategies in a clinical practice guideline issued by the American Heart…
- MONDAY, Feb. 23, 2026 — Ultra-endurance running accelerates red blood cell (RBC) aging through inflammatory and oxidative pathways, according to a study published online Feb. 18 in Blood Red Cells & Iron.Travis Nemkov, Ph.D., from the…
- MONDAY, Feb. 23, 2026 — For individuals with high blood pressure (BP), baduanjin, a traditional Chinese mind-body practice, can lower systolic BP (SBP), with effects sustained for 52 weeks, according to a study published online Feb. 18 in the…
- MONDAY, Feb. 23, 2026 — Sugar-sweetened beverages (SSBs) are positively associated with anxiety among adolescents, according to a review published online Feb. 10 in the Journal of Human Nutrition and Dietetics.Karim Khaled, Ph.D., from the…
- MONDAY, Feb. 23, 2026 — Clinical features and outcomes of injection drug use-associated endogenous endophthalmitis (IDU-EE) are described in a study published online Jan. 13 in Ophthalmology Retina.Jared T. Sokol, M.D., from the University of…
- MONDAY, Feb. 23, 2026 — Fine particulate matter (PM2.5) exposure is directly associated with an increased risk for Alzheimer disease (AD), according to a study published online Feb. 17 in PLOS Medicine. Yanling Deng, from Rollins School of Public…
Thông tin từ The Pharma Letter
- Switzerland’s Sandoz has reported that the European Commission has granted marketing authorization for Ranluspec, a biosimilar ophthalmology drug referencing Lucentis (ranibizumab).
- The European Commission (EC) has approved an extension of Johnson & Johnson’s Rybrevant (amivantamab) marketing authorization to include additional subcutaneous (SC) dosing regimens.
- The pharmaceutical industry in Denmark made a significant impact on GDP growth in 2025, but lost steam towards the end of the year, says trade group Lif.
- The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for the medicine Brinsupri (brensocatib) to treat patients 12 years and older with non-cystic fibrosis bronchiectasis (NCFB) who have experienced two or more flare-ups or worsening of symptoms in the past 12 months.
- In a major ruling on Friday, the US Supreme Court struck down the bulk of President Donald Trump’s global tariff program, concluding that his administration lacked legal authority under the International Emergency Economic Powers Act (IEEPA) to impose broad import taxes without explicit congressional approval.
- Swiss pharma giant Novartis today revealed that it has entered into an agreement with the ChrysCapital group, one of the largest private equity firms investing in India, to transfer its 70.68% shareholding in Novartis India Limited (NIL).
Thông tin từ BioPharmaDive
- At an event on Monday, the agency officially unveiled long-awaited draft guidance meant to help speed the development of bespoke treatments for extremely rare diseases.
- Shares fell by more than 15% on results showing study participants receiving Novo’s CagriSema lost less weight than those who took Lilly’s Zepbound.
- Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.
- The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.
- VHH antibodies: they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But with great power comes great challenges!
- Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.
Thông tin từ STAT News
- In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.
- Bayer sued rival Johnson & Johnson for launching a “false advertising campaign” based on flawed data to wrongfully promote its drug as more effective.
- The FDA expects a flood of applications for a new "plausible mechanism pathway" for approval of bespoke gene-editing treatments.
- Would you trust AI to help you pick your Medicare plan?
- The No. 2 official at the CDC has resigned, adding to the drama and chaos surrounding the agency's leadership.
- And other biotech news brought to you by The Readout
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 20 February 2026; doi:10.1038/d41573-026-00027-3The pancreatic cancer drug market
- Nature Reviews Drug Discovery, Published online: 20 February 2026; doi:10.1038/d41573-026-00032-6Clearing cholesterol combats secondary lymphoedema
- Nature Reviews Drug Discovery, Published online: 18 February 2026; doi:10.1038/d41573-026-00030-8PIP4K2C: an emerging fulcrum for multiple diseases
- Nature Reviews Drug Discovery, Published online: 16 February 2026; doi:10.1038/d41573-026-00031-7Drug developers spent billions of dollars on clinical trials of TIGIT-blocking cancer immunotherapies, but have little to show for it. What went wrong?
- Nature Reviews Drug Discovery, Published online: 16 February 2026; doi:10.1038/s41573-025-01370-7Neuroimmune interactions shape neurodegenerative disease progression. This Review examines how microglia integrate signals from central and peripheral immune cells, outlines emerging therapeutic targets beyond core pathology, and discusses the growing need for immune-based biomarkers in Alzheimer’s disease and related disorders.
- Nature Reviews Drug Discovery, Published online: 13 February 2026; doi:10.1038/d41573-026-00028-2Approvals by the China NMPA in 2025